Meningioma: current treatment options and future directions
- PMID: 15509483
- DOI: 10.1007/s11864-004-0038-y
Meningioma: current treatment options and future directions
Abstract
Benign meningiomas can be observed if not symptomatic or growing. When treatment is indicated, the options are surgery, radiosurgery, fractionated radiation therapy, or a combination of these modalities. Except in certain cases, such as large tumors that require debulking for relief of symptoms, we do not recommend the routine use of combination therapy. Intracranial meningiomas have usually been treated with surgical resection with an expected durable local control of 80% to 90% when a gross total resection (GTR) is obtained. Patients who have inoperable disease, refuse surgery, undergo less than a GTR, or who have aggressive histology should instead be considered candidates for radiation therapy or radiosurgery. While benign meningiomas can be successfully treated definitively or postoperatively with either fractionated radiation therapy or single fraction radiosurgery, atypical or malignant lesions are best treated with fractionated radiation therapy with conventional dosimetric margins. The role of systemic therapy is not yet defined, but multiple agents are being investigated in early phase trials for patients with recurrent or progressive disease after standard therapy has failed.
Similar articles
-
Multimodal treatment of parasagittal meningiomas: a single-center experience.J Neurosurg. 2017 Dec;127(6):1249-1256. doi: 10.3171/2016.9.JNS161859. Epub 2017 Feb 3. J Neurosurg. 2017. PMID: 28156245
-
Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal?J Neurosurg. 1994 Feb;80(2):187-90. doi: 10.3171/jns.1994.80.2.0187. J Neurosurg. 1994. PMID: 8283254 No abstract available.
-
Management of Atypical and Anaplastic Meningiomas.Neurosurg Clin N Am. 2016 Apr;27(2):239-47. doi: 10.1016/j.nec.2015.11.003. Epub 2016 Feb 20. Neurosurg Clin N Am. 2016. PMID: 27012388 Review.
-
Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.Strahlenther Onkol. 2006 Nov;182(11):641-6. doi: 10.1007/s00066-006-1555-3. Strahlenther Onkol. 2006. PMID: 17072521
-
Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.Neurosurg Focus. 2019 Jun 1;46(6):E2. doi: 10.3171/2019.3.FOCUS1970. Neurosurg Focus. 2019. PMID: 31153149
Cited by
-
Medical management of meningiomas.CNS Oncol. 2013 Mar;2(2):161-70. doi: 10.2217/cns.13.6. CNS Oncol. 2013. PMID: 25057977 Free PMC article. Review.
-
Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma.J Neurooncol. 2021 Jun;153(2):211-222. doi: 10.1007/s11060-021-03739-1. Epub 2021 Mar 26. J Neurooncol. 2021. PMID: 33768405 Free PMC article.
-
The current status of 5-ALA fluorescence-guided resection of intracranial meningiomas-a critical review.Neurosurg Rev. 2015 Oct;38(4):619-28. doi: 10.1007/s10143-015-0615-5. Epub 2015 Mar 5. Neurosurg Rev. 2015. PMID: 25736455 Free PMC article. Review.
-
SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery.Acta Neurochir (Wien). 2018 Aug;160(8):1539-1546. doi: 10.1007/s00701-018-3575-z. Epub 2018 Jun 1. Acta Neurochir (Wien). 2018. PMID: 29858948 Free PMC article.
-
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.J Neurooncol. 2011 Sep;104(3):765-71. doi: 10.1007/s11060-011-0541-5. Epub 2011 Feb 13. J Neurooncol. 2011. PMID: 21318318
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources